AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33760089 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally designed gamification intervention with a social support partner (12-week duration)
Number of subjects: 232
Study 33760089 — intervention group
Group type: COMPARATOR
Intervention: Control group received feedback from the wearable device only
Number of subjects: 232
Study 33760089 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 232
Study 32130757 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral symptom abstinence plus meaningful reduction in EDE global scores
Number of subjects: 110
Study 32130757 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral abstinence alone
Number of subjects: 110
Study 32130757 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher EOT EDE global scores
Number of subjects: 110
Study 35421999 — intervention group
Group type: EXPERIMENTAL
Intervention: navigation services
Number of subjects: 670
Study 35421999 — intervention group
Group type: COMPARATOR
Intervention: electronic brochure
Number of subjects: 670
Study 35421999 — intervention group
Group type: EXPERIMENTAL
Intervention: critical dialog or brief counseling
Number of subjects: 670
Study 34887491 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice-assisted AI coaching (MyCoach)
Number of subjects: 42
Study 34887491 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous AI coaching (SmartText)
Number of subjects: 42
Study 34887491 — intervention group
Group type: COMPARATOR
Intervention: Control (health information)
Number of subjects: 42
Study 36107571 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether emulsion (1%)
Number of subjects: 60
Study 36107571 — intervention group
Group type: COMPARATOR
Intervention: Emulsion base
Number of subjects: 60
Study 33130059 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin solution (5 mg/mL) soaking for 30 minutes
Number of subjects: 2
Study 33130059 — intervention group
Group type: COMPARATOR
Intervention: Normal saline soaking for 30 minutes
Number of subjects: 2
Study 36104122 — intervention group
Group type: EXPERIMENTAL
Intervention: SHAW educational programme plus access to the dayzz app for up to 9 months
Number of subjects: 1355
Study 36104122 — intervention group
Group type: COMPARATOR
Intervention: Control group (received intervention at month 10)
Number of subjects: 1355
Study 34352719 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-session transition intervention led by registered nurses
Number of subjects: 57
Study 34352719 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-session transition intervention
Number of subjects: 57
Study 34352719 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 57
Study 32379010 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-week HIIT intervention (3 sessions/week)
Number of subjects: 0
Study 32379010 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33176392 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oxytocin
Number of subjects: 1008
Study 33176392 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oxytocin
Number of subjects: 1008
Study 32249707 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall of a positive memory
Number of subjects: 342
Study 32249707 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagine a future positive event
Number of subjects: 342
Study 32249707 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall of a negative memory
Number of subjects: 342
Study 32249707 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagine a future negative event
Number of subjects: 342
Study 35438091 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFAs) and phytosterol ester (PSE) co-supplementation
Number of subjects: 31
Study 33845783 — intervention group
Group type: EXPERIMENTAL
Intervention: C2C6AR (the ratio of the angle between a line passing through the bottom of the second cervical vertebra and a line passing through the bottom of the sixth cervical vertebra in the extension position and the one in the neutral position)
Number of subjects: 270
Study 33845783 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mallampati test (MMT)
Number of subjects: 270
Study 33845783 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyomental distance (HMD)
Number of subjects: 270
Study 33845783 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyomental distance ratio (HMDR)
Number of subjects: 270
Study 33845783 — intervention group
Group type: EXPERIMENTAL
Intervention: C2C6AR
Number of subjects: 270
Study 32217917 — intervention group
Group type: EXPERIMENTAL
Intervention: Midurethral sling (MUS)
Number of subjects: 17953
Study 33597005 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel diabetic therapeutic footwear (n = 160)
Number of subjects: 320
Study 33597005 — intervention group
Group type: COMPARATOR
Intervention: Own footwear (n = 160)
Number of subjects: 320
Study 35732845 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 oz prunes daily plus docusate sodium 100 g twice daily
Number of subjects: 77
Study 35732845 — intervention group
Group type: COMPARATOR
Intervention: Docusate alone
Number of subjects: 77
Study 33971153 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonelokimab
Number of subjects: 310
Study 33971153 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab
Number of subjects: 310
Study 32771424 — intervention group
Group type: EXPERIMENTAL
Intervention: LSG with antral resection (Group A)
Number of subjects: 279
Study 32771424 — intervention group
Group type: COMPARATOR
Intervention: LSG with antral preservation (Group B)
Number of subjects: 279
Study 35662148 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based universal depression screening
Number of subjects: 0
Study 35662148 — intervention group
Group type: COMPARATOR
Intervention: Standard symptom-based depression recognition
Number of subjects: 0
Study 34006912 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration protocol (HP)
Number of subjects: 28
Study 34006912 — intervention group
Group type: COMPARATOR
Intervention: Control protocol (CP)
Number of subjects: 28
Study 32807539 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching intervention combining lay language, simplified handouts, provision of an unmarked dosing syringe, and teach-back to confirm correct dosing.
Number of subjects: 149
Study 32807539 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 149
Study 32807539 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching intervention.
Number of subjects: 149
Study 32807539 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching intervention (adjusted for health literacy and language).
Number of subjects: 149
Study 36134918 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 3503
Study 36134918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3503
Study 34526079 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (AC)
Number of subjects: 120
Study 34526079 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SAC)
Number of subjects: 120
Study 32669375 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganetespib (200 mg/m2, days 1 and 15) with pemetrexed (500 mg/m2, day 1) and cisplatin (75 mg/m2, day 1) or carboplatin (AUC 5, day 1)
Number of subjects: 27
Study 32669375 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganetespib at MTD (200 mg/m2)
Number of subjects: 27
Study 32669375 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganetespib
Number of subjects: 27
Study 34971646 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut allergen powder-dnfp (PTAH)
Number of subjects: 944
Study 34971646 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut allergen powder-dnfp (PTAH) during updosing
Number of subjects: 944
Study 34971646 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut allergen powder-dnfp (PTAH) during 300 mg maintenance
Number of subjects: 944
Study 33440019 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol total intravenous anaesthesia
Number of subjects: 146
Study 33440019 — intervention group
Group type: COMPARATOR
Intervention: Volatile-based maintenance anaesthesia
Number of subjects: 146
Study 35042289 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics nomogram model
Number of subjects: 114
Study 35042289 — intervention group
Group type: COMPARATOR
Intervention: Radiomics model (12 optimal radiomics features)
Number of subjects: 114
Study 35042289 — intervention group
Group type: COMPARATOR
Intervention: Clinical relevant factors model (residual disease, neutrophil count, carbohydrate antigen 199)
Number of subjects: 114
Study 32654042 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-surgical logopedic rehabilitative training (Group A)
Number of subjects: 260
Study 32654042 — intervention group
Group type: COMPARATOR
Intervention: No post-surgical treatment (Group B)
Number of subjects: 260
Study 35928080 — intervention group
Group type: EXPERIMENTAL
Intervention: Fallopian Tube Sperm Perfusion (FSP)
Number of subjects: 160
Study 35928080 — intervention group
Group type: COMPARATOR
Intervention: Standard IUI (sIUI)
Number of subjects: 160
Study 32214138 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 66
Study 32214138 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (less favorable treatment response)
Number of subjects: 66
Study 33509804 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg metformin
Number of subjects: 34
Study 33509804 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 mg metformin
Number of subjects: 34
Study 33509804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 33509804 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (both dosages)
Number of subjects: 34
Study 32320773 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage and imiquimod cream
Number of subjects: 145
Study 32320773 — intervention group
Group type: COMPARATOR
Intervention: Surgical excision
Number of subjects: 145
Study 33555670 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossfit® (CF)
Number of subjects: 0
Study 33555670 — intervention group
Group type: EXPERIMENTAL
Intervention: LesMills® (LM)
Number of subjects: 0
Study 33555670 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional resistance (TRAD)
Number of subjects: 0
Study 33555670 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 33280441 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalus membranaceus polysaccharide (APS) treatment
Number of subjects: 90
Study 33280441 — intervention group
Group type: COMPARATOR
Intervention: Control (saline injection)
Number of subjects: 90
Study 33280441 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected group (goslings inoculated with goose parvovirus)
Number of subjects: 90
Study 35975697 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-Based Outcome (GBO) tool
Number of subjects: 0
Study 35975697 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 32700919 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigenously adapted cognitive‐behavioral therapy for excessive smartphone use (IACBT‐ESU)
Number of subjects: 62
Study 32700919 — intervention group
Group type: COMPARATOR
Intervention: Brief educational data alone (Control)
Number of subjects: 62
Study 36251032 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic A
Number of subjects: 48
Study 36251032 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic B
Number of subjects: 48
Study 36251032 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic C
Number of subjects: 48
Study 36251032 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic D
Number of subjects: 48
Study 36251032 — intervention group
Group type: COMPARATOR
Intervention: L-asparaginase Medac (historical control)
Number of subjects: 48
Study 32213316 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin (9 million units loading dose, followed by 4.5 MU twice daily maintenance dose)
Number of subjects: 406
Study 32213316 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin exposure
Number of subjects: 406
Study 32213316 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFA score at baseline
Number of subjects: 406
Study 32213316 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 406
Study 32213316 — intervention group
Group type: EXPERIMENTAL
Intervention: Acinetobacter or Pseudomonas as index pathogen
Number of subjects: 406
Study 34086087 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary resection anastomosis (PRA)
Number of subjects: 78
Study 34086087 — intervention group
Group type: COMPARATOR
Intervention: Hartmann's procedure (HP)
Number of subjects: 78
Study 32811480 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth intervention with personalized data integration from primary care EHR
Number of subjects: 934
Study 32811480 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth intervention
Number of subjects: 934
Study 35132659 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVH
Number of subjects: 103
Study 35132659 — intervention group
Group type: COMPARATOR
Intervention: non-CVVH
Number of subjects: 103
Study 34582552 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 cup of coffee (1C)
Number of subjects: 21
Study 34582552 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cups of coffee (3C)
Number of subjects: 21
Study 34582552 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 cup of coffee + 2 CBPCC twice daily (PC)
Number of subjects: 21
Study 34582552 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study 33484509 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy with manual therapy
Number of subjects: 60
Study 33484509 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 60
Study 32304216 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring care (RC)
Number of subjects: 600
Study 32304216 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 600
Study 34346946 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement sealant (Clinpro XT Varnish; 3M ESPE)
Number of subjects: 27
Study 34346946 — intervention group
Group type: COMPARATOR
Intervention: Topical fluoride varnish application (Duraphat; Colgate)
Number of subjects: 27
Study 33982280 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR intervention (family‐tailored education and problem‐solving behavioral intervention)
Number of subjects: 200
Study 33982280 — intervention group
Group type: COMPARATOR
Intervention: EO intervention (education only)
Number of subjects: 200
Study 35596932 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine (ESK)
Number of subjects: 0
Study 35596932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33682440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic stroke
Number of subjects: 4832
Study 33682440 — intervention group
Group type: COMPARATOR
Intervention: Transient ischemic attack (TIA)
Number of subjects: 4832
Study 33682440 — intervention group
Group type: EXPERIMENTAL
Intervention: Reclassified ischemic stroke
Number of subjects: 4832
Study 32301894 — intervention group
Group type: EXPERIMENTAL
Intervention: TKDT granule (once per day for 24 weeks)
Number of subjects: 104
Study 32301894 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once per day for 24 weeks)
Number of subjects: 104
Study 35448996 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice change intervention (multi-strategy intervention over 7 months)
Number of subjects: 5694
Study 33837095 — intervention group
Group type: EXPERIMENTAL
Intervention: ePROMs plus graphical displays of ePROM results to treating clinicians in consultations
Number of subjects: 0
Study 33837095 — intervention group
Group type: COMPARATOR
Intervention: ePROMs without graphical display of ePROM results
Number of subjects: 0
Study 32858717 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage (daily 30-minute massage for 7 days)
Number of subjects: 60
Study 32858717 — intervention group
Group type: COMPARATOR
Intervention: Control (daily 30-minute restriction of nonessential caregiving for 7 days)
Number of subjects: 60
Study 35488477 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Bone Regeneration (GBR)
Number of subjects: 14
Study 35488477 — intervention group
Group type: EXPERIMENTAL
Intervention: Socket Seal (SS)
Number of subjects: 14
Study 35488477 — intervention group
Group type: COMPARATOR
Intervention: Control (unassisted socket healing)
Number of subjects: 14
Study 34936740 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent diagnostic strategy (on-site molecular testing, guided restructuring of clinic workflows, monthly feedback of quality metrics)
Number of subjects: 10644
Study 34936740 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent diagnostic strategy
Number of subjects: 10644
Study 34936740 — intervention group
Group type: COMPARATOR
Intervention: Routine care (on-site sputum-smear microscopy and referral-based molecular testing)
Number of subjects: 10644
Study 34474649 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalation to first biologic
Number of subjects: 100
Study 34474649 — intervention group
Group type: COMPARATOR
Intervention: Escalation in csDMARDs
Number of subjects: 100
Study 32120028 — intervention group
Group type: EXPERIMENTAL
Intervention: Liothyronine (L-T3) 75 mcg total daily dose (TDD)
Number of subjects: 15
Study 32120028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 32120028 — intervention group
Group type: EXPERIMENTAL
Intervention: Liothyronine (L-T3)
Number of subjects: 15
Study 33881368 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0
Study 33881368 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Number of subjects: 0
Study 36053820 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 887
Study 36053820 — intervention group
Group type: COMPARATOR
Intervention: BIAsp 30
Number of subjects: 887
Study 34959798 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose beverage (125 mL semi-skimmed milk and 50 g glucose)
Number of subjects: 11
Study 34959798 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent sucrose beverage (125 mL semi-skimmed milk and 50 g sucrose)
Number of subjects: 11
Study 34959798 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose beverage (125 mL semi-skimmed milk and 50 g sucrose)
Number of subjects: 11
Study 34959798 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomaltulose beverage (125 mL semi-skimmed milk and 50 g isomaltulose)
Number of subjects: 11
Study 36304565 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 genotype treatment (G)
Number of subjects: 0
Study 36304565 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (S)
Number of subjects: 0
Study 32662840 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy at a power of 2 J/cm2 with a total of 4-6 J energy over each implant
Number of subjects: 30
Study 32662840 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 32662840 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 30
Study 34937512 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant corifollitropin alfa combined with highly purified urinary gonadotropin
Number of subjects: 51
Study 34937512 — intervention group
Group type: COMPARATOR
Intervention: Recombinant follitropin/lutropin alfa within the protocol of applying gonadotropin-releasing hormone antagonists
Number of subjects: 51
Study 35007129 — intervention group
Group type: EXPERIMENTAL
Intervention: LSVT‐1701, 6 mg/kg single dose
Number of subjects: 32
Study 35007129 — intervention group
Group type: EXPERIMENTAL
Intervention: LSVT‐1701, 1.5 mg/kg twice daily for 4 days
Number of subjects: 32
Study 35007129 — intervention group
Group type: EXPERIMENTAL
Intervention: LSVT‐1701, 3 mg/kg twice daily for 4 days
Number of subjects: 32
Study 35007129 — intervention group
Group type: EXPERIMENTAL
Intervention: LSVT‐1701, 4.5 mg/kg twice daily for 4 days
Number of subjects: 32
Study 35007129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 33409684 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of meropenem (3 g daily) for 48 hours
Number of subjects: 15
Study 33409684 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted dose of meropenem based on Cockcroft‐Gault equation
Number of subjects: 15
Study 33409684 — intervention group
Group type: COMPARATOR
Intervention: Standard and adjusted doses of meropenem
Number of subjects: 15
Study 34733454 — intervention group
Group type: EXPERIMENTAL
Intervention: PACU experimental group
Number of subjects: 135
Study 34733454 — intervention group
Group type: COMPARATOR
Intervention: PACU control group
Number of subjects: 135
Study 34733454 — intervention group
Group type: COMPARATOR
Intervention: OR group
Number of subjects: 135
Study 32984892 — intervention group
Group type: EXPERIMENTAL
Intervention: sACE2 protein level measured by Olink Proteomics® Multiplex CVD II96 × 96 panel
Number of subjects: 5087
Study 32984892 — intervention group
Group type: EXPERIMENTAL
Intervention: sACE2 level
Number of subjects: 5087
Study 32984892 — intervention group
Group type: EXPERIMENTAL
Intervention: sACE2 level adjusted for biomarkers
Number of subjects: 5087
Study 32984892 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF‐15 and NT‐proBNP levels
Number of subjects: 5087
Study 33073598 — intervention group
Group type: EXPERIMENTAL
Intervention: Offering one fixed BSS appointment
Number of subjects: 1908
Study 33073598 — intervention group
Group type: EXPERIMENTAL
Intervention: Offering two fixed BSS appointments
Number of subjects: 1908
Study 33073598 — intervention group
Group type: EXPERIMENTAL
Intervention: Offering four fixed BSS appointments
Number of subjects: 1908
Study 33073598 — intervention group
Group type: EXPERIMENTAL
Intervention: Offering six fixed BSS appointments
Number of subjects: 1908
Study 32114502 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib monotherapy (100 mg twice daily)
Number of subjects: 77
Study 32114502 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib combined with pembrolizumab (200 mg on day 1 of each 3-week cycle)
Number of subjects: 77
Study 33548529 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive (MIS) endoscopic ICH evacuation
Number of subjects: 21